Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.
Recent stutdies have suggested that much of the success of ustekinumab, the combined IL-12/23 inhibitor, may be most attributable to the inhibition of IL-23 alone.
Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.
Three new FDA approvals, proteomics, cancer, infectious risk, nonadherence and disappointing clinical trial results covered in this RheumNow Week in Review.
BMJ has reported the results of a case-control study that analyzed the risk of hospitalization from heart failure associated with the use of NSAIDs amongst healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom).
A year ago, physicians panicked with a new and formidable change in practice called ICD-10. This newer and more complex coding system had the angst of Y2K and nearly as much true trouble - largely because of the "relaxed" stance taken by CMS with its introduction.
However, the grace period ends on Oct. 1, 2016 and henceforth CMS will require the highest level of specificity in coding.
Travel can be challenging for arthritis patients. Here are some useful tips to travel smoothly and pain free.
Rates of serious infection and mortality among patients with systemic lupus erythematosus (SLE) did not depend on the immunosuppressive drug regimen they were on, investigators reported.
Rheumatologists in Georgia and across the country are under extreme pressure to care for our patients. The Georgia Society of Rheumatology exists to stimulate interest and increase knowledge of arthritis and rheumatic diseases among physicians, allied health professionals, and lay advocates. Following are highlights of GRS issues and activities.
Ilaris was previously approved for use in systemic JIA and CAPS. The FDA has expanded this to include TRAPS, Hyper-IgD and FMF based on clinical trials.
Romosozumab is being developed as a novel therapy for osteoporosis. It is a monoclonal antibody that binds sclerostin, and has been shown to increase bone formation while decreasing bone resorption.
2016 has been a big year for biosimilars in rheumatology.
On Friday, the FDA announced the approval of Amgen's biosimilar version of Humira. The approval comes roughly 10 weeks after the FDA's Arthritis Advisory Committee unanimously voted, 26-0, in favor of approving ABP 501 based on clinical trials in rheumatoid arthritis (RA) and plaque psoriasis.
The anti-IL-12/IL-23 inhibitor, Stelara (ustekinumab) has been FDA approved for the treatment of psoriasis and psoriatic arthritis. In the last week, the EMA's CHMP has recommended that the drug also be approved for use in Crohn's disease.Today the FDA approved Stelara for use in adults with moderate to severely active Crohn's disease.
Dr. Jack Cush reviews highlights, news and articles from the past week at RheumNow.com:
